Citalopram and suicidality in adult major depression and anxiety disorders

References

• Cullberg, J. [Suicide and SSRI preparations. Antidepressive agents without psychotherapy are more hazardous than beneficial]. Lakartidningen 1997;94:1409–11, [In Swedish].
   Google Scholar
• Isacsson G. Suicide prevention – A medical breakthrough?. Acta Psychiatr Scand 2000; 102: 113–7
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Ellis SP, Li S, Shuhu AL, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985–1999. J Clin Psychiatry 2004; 65: 1456–62
   PubMed Web of Science ®Google Scholar
• Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991–2000: Trend analysis. Br Med J 2003; 326: 1008
   PubMed Web of Science ®Google Scholar
• Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: A controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005; 111: 286–90
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr, Heiligenstein JH, et al. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment of depression. BMJ 1991; 303: 685–92
   PubMed Web of Science ®Google Scholar
• Montgomery, S, Cronholm, BMA, Montgomery, DB. Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmacol 1978;577S–580S.
   Google Scholar
• Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995; 5: 5–13
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9
   PubMed Web of Science ®Google Scholar
• Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86: 138–45
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Rasmussen JG, Lyby K, Connor P, Tanghøj P. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992; 6(Suppl 5)65–70
   PubMedGoogle Scholar
• Montgomery SA, Rasmussen JG, Tanghøj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181–8
   PubMed Web of Science ®Google Scholar
• Feighner JP, Overø K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999; 60: 824–30
   PubMed Web of Science ®Google Scholar
• Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 1999; 9: 54–60
   PubMedGoogle Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–7
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44–9
   PubMed Web of Science ®Google Scholar
• Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S, Stein DJ, Hedegaard KB, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16: 75–86
   PubMed Web of Science ®Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322–7
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10(Suppl 1)29–35
   PubMedGoogle Scholar
• Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528–34
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Death and dependence: Current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 2003; 17: 355–64
   PubMed Web of Science ®Google Scholar
• Balon R. Reflections on relevance: Psychotherapy and Psychosomatics in 2003. Psychother Psychosom 2004; 73: 5–9
   PubMedGoogle Scholar
• Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo. Analysis of FDA reports. Am J Psychiatry 2003; 160: 790–2
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001; 4: 113–8
   PubMed Web of Science ®Google Scholar
• Ryan HF, Merrill FB, Scott GE, Krebs R, Thompson BL. Increase in suicidal thoughts and tendencies association with diazepam therapy. J Am Med Assoc 1968; 203: 1137–9
   PubMed Web of Science ®Google Scholar
• Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ. 2005; 330: 396–9
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001; 4: 113–8
   PubMed Web of Science ®Google Scholar
• Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 2004; 184: 41–7
   PubMed Web of Science ®Google Scholar
• Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330: 385–8
   PubMed Web of Science ®Google Scholar
• Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: Nested case–control study. BMJ 2005; 330: 389–93
   PubMed Web of Science ®Google Scholar
• Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41–7
   PubMed Web of Science ®Google Scholar
• Trivedi, MH, Rush, J, Wisniewski, SR, Nierenberg, AA, Warden, D, Ritz, L, Norquist, G, Howland, RH, Lebowitz, B, McGrath, PJ, Shores-Wilson, K, Biggs, MM, Balasubramani, GK, Fava, M, STAR*D. Study Team Evaluation of outcomes with citalopram for depression using measurement-based Care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28–40.
   PubMed Web of Science ®Google Scholar